- Home
- YYAI vs CANF Comparison
YYAI vs CANF Comparison
Compare YYAI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YYAI
- CANF
- Stock Information
- Founded
- YYAI 2015
- CANF 1994
- Country
- YYAI Hong Kong
- CANF Israel
- Employees
- YYAI N/A
- CANF N/A
- Industry
- YYAI
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- YYAI
- CANF Health Care
- Exchange
- YYAI NYSE
- CANF Nasdaq
- Market Cap
- YYAI 12.9M
- CANF 14.8M
- IPO Year
- YYAI N/A
- CANF N/A
- Fundamental
- Price
- YYAI $0.80
- CANF $1.08
- Analyst Decision
- YYAI
- CANF Strong Buy
- Analyst Count
- YYAI 0
- CANF 2
- Target Price
- YYAI N/A
- CANF $14.00
- AVG Volume (30 Days)
- YYAI 179.5K
- CANF 70.8K
- Earning Date
- YYAI 08-05-2025
- CANF 06-17-2025
- Dividend Yield
- YYAI N/A
- CANF N/A
- EPS Growth
- YYAI N/A
- CANF N/A
- EPS
- YYAI N/A
- CANF N/A
- Revenue
- YYAI N/A
- CANF $674,000.00
- Revenue This Year
- YYAI N/A
- CANF $461.72
- Revenue Next Year
- YYAI N/A
- CANF N/A
- P/E Ratio
- YYAI N/A
- CANF N/A
- Revenue Growth
- YYAI N/A
- CANF N/A
- 52 Week Low
- YYAI $0.35
- CANF $0.98
- 52 Week High
- YYAI $18.96
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- YYAI 46.50
- CANF 44.23
- Support Level
- YYAI $0.77
- CANF $1.02
- Resistance Level
- YYAI $0.86
- CANF $1.12
- Average True Range (ATR)
- YYAI 0.06
- CANF 0.03
- MACD
- YYAI -0.01
- CANF 0.02
- Stochastic Oscillator
- YYAI 26.13
- CANF 60.00
About YYAI CONNEXA SPORTS TECHNOLOGIES IN
Connexa Sports Technologies Inc operates in the sports equipment and technology business. It is a connected sports company delivering products, technologies, and services across the Watch, Play, Learn commercial and subscription-as-a-service activities in sports. The company's offerings include Slinger Launcher, which is comprised of a portable tennis ball launcher, a portable padel tennis ball launcher, and a portable pickleball launcher. Through Gameface, it provides AI technology and performance analytics.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).